FibrosisToday's news release, "Announced on May 23, 2023 the completion of CHRP collaboration with McMaster University with encouraging results evaluating PGX-processed YBG for interstitial lung diseases."
Here's what the May 23, 2023 news release stated:
"If these results are replicated in human trials, this treatment approach could profoundly change the landscape of fibrotic lung disease therapeutics,” added Dr. Martin Kolb, a respected Pulmonologist and Professor of Medicine at McMaster University."
Today's news release:
"These results triggered presentations at International scientific conferences confirming that PGX-YBG is suitable for inhalation and can act through a newly discovered mechanism of action through specific binding on white blood cells (macrophages) involved in the inflammation and fibrotic process. A comprehensive scientific article was recently submitted to the Biomaterials scientific journal."